

**Open Access**

Oral presentation

## Once-a-day pediatric HAART with DDI+3TC+EFV in Burkina Faso. A phase II trial (ANRS 12103 trial)

Philippe Msellati<sup>\*1</sup>, Boubacar Nacro<sup>2</sup>, Emmanuelle Zoure<sup>2</sup>, Hervé Hien<sup>3</sup>, Hassane Tamboura<sup>2</sup>, François Rouet<sup>3</sup>, Serge Diagbouga<sup>3</sup>, Adama Ouiminga<sup>3</sup>, Ali Drabo<sup>3</sup>, Souleymane Yaméogo<sup>3</sup>, Hélène Peyrière<sup>4</sup>, Olivier Mathieu<sup>4</sup>, Joëlle Nicolas<sup>4</sup> and Philippe Van de Perre<sup>4</sup>

Address: <sup>1</sup>UMR 145 IRD, Bobo-Dioulasso, Burkina Faso, <sup>2</sup>Department of Pediatrics, CHU de Bobo-Dioulasso, Burkina Faso, <sup>3</sup>Centre Muraz, Bobo-Dioulasso, Burkina Faso and <sup>4</sup>Laboratory of Medical Pharmacology and Laboratory of Virology, Montpellier University Hospital, Montpellier, France

\* Corresponding author

from Fourth Dominique Dormont International Conference. Host-Pathogen Interactions in Chronic Infections  
Paris, France. 13-15 December 2007

Published: 9 April 2008

*Retrovirology* 2008, **5**(Suppl 1):O26 doi:10.1186/1742-4690-5-S1-O26

This abstract is available from: <http://www.retrovirology.com/content/5/S1/O26>

© 2008 Msellati et al.; licensee BioMed Central Ltd.

### Background

Simplification of the administration of HAART in children should improve compliance and efficacy of these treatments. Combination of 3TC + DDI + EFV in a single daily oral administration is one option. However, pharmacokinetics, tolerance and efficacy of such once-a-day HAART have not been assessed in children. The ANRS 12103 trial is a phase II on pharmacokinetics, tolerance and compliance of a once-a-day pediatric DDI+3TC+EFV in Burkina Faso.

### Material and methods

ANRS 12103 is an ongoing Open Phase II Trial with a 12 months follow up. 50 HIV-1 infected children eligible for HAART had to be included. Inclusion criteria were: weight  $\geq 10$  kg and aged 30 months to 15 years, naive of ARV treatment and eligible for HAART. Children received efavirenz + 3TC (8mg/kg) + DDI (240mg/m<sup>2</sup>). Clinical examination was performed weekly until M3, then monthly. Pharmacokinetics (plasma C<sub>min</sub> and C<sub>max</sub>) was done at day 15. Quarterly RNA HIV-1, CD4 counts, haematology and biochemistry are performed.

### Results

Enrolment was from February to November 2006 and 98 HIV-infected children have been screened for eligibility criteria: 45 were excluded, one died before inclusion and 52 were included. Among included children there was 21 girls and 31 boys, mean age was 6.8 years, Zscore Weight for Age (W/A) and Height for Age (H/A) were respectively -1.91 and -1.99 at inclusion. Mean CD4 was 355/ $\mu$ l (mean CD4 percentage 9%), and median HIV-1 RNA 5.50 Log<sub>10</sub> cp/ml. Among the 52 expected samples for minimum concentration of efavirenz, 50 were obtained. Thirty children were in the expected ranges (60.1%), 11 (22%) below therapeutic levels and 9 (18%) above therapeutic levels. Maximum concentrations were in the expected ranges in 23/49 children (47%), below therapeutic levels in 3/49 children (6%) and over in 23/49 children. Dosages of 3TC and DDI are ongoing.

At 9 months of follow-up, two children had died, Zscore W/A and H/A were respectively -1.37 and -1.62, and mean CD4 was 893/ $\mu$ l (mean CD4 percentage 20%). HIV-1 RNA was below detectable level (300 copies/ml) in 39 children (76%) and below 1000 copies/ml in two children (4%). Two HAART adverse effect occurred. One cuta-

neous eruption with a temporary stop and successful reintroduction and one increase in liver enzymes.

## Conclusion

Preliminary data of this phase II trial suggest that once-a-day DDI+3TC+EFV in children provides satisfactory plasma concentration for EFV, and is associated with virological success and immune restoration. At 9-month follow up, it is effective and well tolerated.

Publish with **BioMed Central** and every scientist can read your work free of charge

*"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."*

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

